Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.64 |
| ▸ | MAOA | P21397 | 8/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13089909 | 0.89 | MAOA (0.59) | CALML3MAOAMAOB | |
| SCHEMBL1378948 | 0.87 | CALML3 (0.65) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL13089915 | 0.86 | MAOA (0.65) | MAOACYP2C9CYP3A4CYP2D6 | |
| SCHEMBL1556067 | 0.79 | CALML3 (0.55) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL1556071 | 0.79 | CALML3 (0.55) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL1557056 | 0.79 | CALML3 (0.53) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL1557053 | 0.79 | CALML3 (0.53) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL1556065 | 0.79 | MAOA (0.63) | CALML3MAOAMAOB | |
| SCHEMBL29432576 | 0.78 | CALML3 (0.77) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL22245049 | 0.78 | CALML3 (0.77) | CALML3MAOAMAOBCYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-02-23 | — | — | US | disclosed |
| US-9163043-B2 | Oxazolidinone derivatives | DONG-A ST CO., LTD. (KR) | 2015-10-20 | — | — | US | disclosed |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2014-11-27 | — | — | US | disclosed |
| US-20130281492-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | TRIUS THERAPEUTICS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130274174-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | TRIUS THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8461188-B2 | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use | TRIUS THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20130102523-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | TRIUS THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8420676-B2 | Oxazolidinone derivatives | DONG-A PHARMACEUTICALS CO. LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049763-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20130281492-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20130102523-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | EIF4EBP1, EIF4E, EIF6 | CALML3 1972/4885MAOA 4539/4885MAOB 4420/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | CALML3 1992/4885MAOA 4398/4885MAOB 4248/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | CALML3 2192/4885MAOA 3819/4885MAOB 3591/4885 |
| US-20140350059-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20130274174-A1 | THERAPEUTIC COMBINATION OF DAPTOMYCIN AND PROTEIN SYNTHESIS INHIBITOR ANTIBIOTIC, AND METHODS OF USE | EIF4EBP1, EIF4E, EIF6 | CALML3 1972/4885MAOA 4539/4885MAOB 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.